Biologics denials: 78.2% overturned by independent reviewers
In 527 California IMR decisions from 2006 to 2026, reviewers overturned the plan 412 times (78.2%). In the last five years: 81.6% of 413. Denials reach IMR only when a member appeals all the way; read the caveats below before generalising.
By diagnosis
| Diagnosis category | Decisions | Overturned | Last 5 years |
|---|---|---|---|
| Digestive System/ GI | 132 | 89.4% | 89.7% of 107 |
| Skin Disorders | 107 | 90.7% | 93.3% of 89 |
| Immuno Disorders | 92 | 70.7% | 73.5% of 68 |
| CNS/ Neuromusc Dis | 37 | 91.9% | 93.1% of 29 |
| Cancer | 23 | 30.4% | 30.8% of 13 |
| Endocrine/Metabolic | 20 | 60.0% | 61.1% of 18 |
| Orth/Musculoskeletal | 20 | 50.0% | 62.5% of 8 |
| GU/ Kidney Disorder | 15 | 80.0% | 84.6% of 13 |
| Genetic Diseases | 14 | 92.9% | 90.0% of 10 |
| Respiratory System | 14 | 85.7% | 100.0% of 11 |
| Vision | 9 | 55.6% | 57.1% of 7 |
| Skin Subcutaneous | 9 | 100.0% | 100.0% of 9 |
| Cardiac/Circ Problem | 7 | 14.3% | 16.7% of 6 |
| Blood Related Disord | 7 | 57.1% | 60.0% of 5 |
| Digest System | 6 | 50.0% | 50.0% of 6 |
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 48 | 83.3% |
| 2022 | 44 | 75.0% |
| 2023 | 63 | 73.0% |
| 2024 | 65 | 86.2% |
| 2025 | 172 | 83.7% |
| 2026 | 21 | 85.7% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 230 | 77.4% | 78.2% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 180 | 88.9% | 78.2% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 84 | 76.2% | 78.2% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 35 | 60.0% | 78.2% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 35 | 11.4% | 78.2% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 33 | 60.6% | 78.2% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 28 | 64.3% | 78.2% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Taltz. The patient has psoriatic arthritis and has shown sustained clinical improvement on Taltz after failing prior biologic therapies, including Enbrel and Cosentyx. The medical records document meaningful improvement in symptoms and function with this treatment. Given the patient’s history of inadequate response to other therapies and …”
“The physician reviewer found that a patient has requested authorization and coverage for Cosentyx UnoReady. In this case, the patient has been diagnosed with plaque psoriasis and psoriatic arthritis (PsA). The record establishes that the patient has tried and failed prior therapies. Given the patient’s joint involvement, systemic treatment is required. Cosentyx is FDA‑approved and has demonstrated efficacy for both …”
“The physician reviewer found that a patient has requested authorization and coverage for Nemluvio. Nemluvio (nemolizumab) is U.S. Food and Drug Administration (FDA)-approved for patients with prurigo nodularis. Clinical trials have shown that Nemluvio is effective in reducing symptoms of prurigo nodularis. In this case, the patient has a diagnosis of prurigo nodularis that has been refractory to other treatments. …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Biologics denials overturned?
In 527 California IMR decisions from 2006 to 2026, reviewers overturned the plan 412 times (78.2%). In the last five years: 81.6% of 413.
What did the reviewers' findings mention in overturned cases?
The table on this page counts keyword matches in the findings: prior therapies tried, contraindications, guidelines cited, published evidence, whether the records supported the request. They describe what the findings say, not why the case was decided.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but the reasoning is the same kind: criteria, documentation and alternatives. Use the findings as a guide to what to document.
Related: California appeal rights · California external-review reversal rate · The levers library · CSV
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.